An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis

Exclusion Criteria

• •Subject with psoriatic erythroderma has involved Body surface area (BSA) of lesion \< 80% at baseline.
• •Subject diagnosed with guttate psoriasis, medication-induced or medication-exacerbated psoriasis.
• •Evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of KHK4827 on psoriasis.
• •Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher infection
• •Subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol.
• •Subject has used Ultra Violet B (UVB) therapy within 14 days of the first dose or Ultra Violet A (UVA) (with or without psoralen) within 28 days of the first dose.
• •Subject has used etanercept, adalimumab, infliximab or ustekinumab within 1 week, 2 weeks, 8 weeks or 12 weeks of the first dose, respectively.
• •Subject has stopped ustekinumab or other anti-Interleukin (IL)-23 biologics therapy due to lack of efficacy
• •Subject has used live vaccine within 3 months of the first dose
• •Subject has previously used an anti-IL-17 biologic therapy